The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference

Monday, October 25, 2010

Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference06:30 EDT Monday, October 25, 2010ANAHEIM, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the 21st Annual Oppenheimer Healthcare Conference at 1:00 p.m. ET on Wednesday, November 3, 2010 at The Waldorf-Astoria Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments.Attendance at this conference is by invitation only. A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available for 90 days after the live presentation, and can also be accessed at www.questcor.com. About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company with products that help patients with serious, difficult-to-treat medical conditions.  Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is approved for the treatment of exacerbations associated with multiple sclerosis and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Questcor will market Acthar for the treatment of patients with infantile spasms, a rare form of refractory childhood epilepsy.  Acthar is also approved for 15 other indications. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.  For more information, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey, Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or Investors: Gregory Gin/Doug Sherk, +1-415-896-6820, Media: Janine McCargo, +1-646-688-0425, both of EVC Group